Spyre Therapeutics宣佈其新型半衰期延長型抗α4β7抗體Spy001用於治

快訊 · 06/18 19:30

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of Spy001, Its Novel Half-Life Extended Anti-Α4Β7 Antibody, for the Treatment of Inflammatory Bowel Disease

Spyre Therapeutics宣佈其新型半衰期延長型抗α4β7抗體Spy001用於治療炎症性腸病的1期試驗首批參與者已經接受給藥。